Business
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centralized transplant rejection testExpect U.K. CE marking via self-certification in Q2 2026Completed $26 million financing in February; funds intended to support expansion into heart transplantation market while also commercializing testing for kidney NASHVILLE, Tenn.,
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ALKr_u67t7mZA65QeGXCrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centralized transplant rejection test","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Expect U.K. CE marking via self-certification in Q2 2026","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed $26 million financing in February; funds intended to support expansion into heart transplantation market while also commercializing testing for kidney","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":487,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:","length":211,"tagName":"p"},{"type":"text","content":"Fellow shareholders,","length":20,"tagName":"p"},{"type":"text","content":"We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review. Our FDA submission this week represents the culmination of 12 years of clinical development and three years of highly focused technical product development.","length":316,"tagName":"p"},{"type":"text","content":"We see many positive signals that the transplant community is ready for GraftAssureDx.","length":86,"tagName":"p"},{"type":"text","content":"In the past three months, we have doubled the number of transplant centers interested in what we are building. We are now en...